Cargando…
IMB0901 inhibits muscle atrophy induced by cancer cachexia through MSTN signaling pathway
BACKGROUND: Cancer cachexia as a metabolic syndrome can lead to at least 25% of cancer deaths. The inhibition of muscle atrophy is a main strategy to treat cancer cachexia. In this process, myostatin (MSTN) can exert a dual effect on protein metabolism, including inhibition of protein biosynthesis a...
Autores principales: | Liu, Dong, Qiao, Xinran, Ge, Zhijuan, Shang, Yue, Li, Yi, Wang, Wendie, Chen, Minghua, Si, Shuyi, Chen, Shu-zhen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437903/ https://www.ncbi.nlm.nih.gov/pubmed/30922397 http://dx.doi.org/10.1186/s13395-019-0193-2 |
Ejemplares similares
-
Brown adipocytes promote epithelial mesenchymal transition of neuroblastoma cells by inducing PPAR-γ/UCP2 expression
por: Ge, Zhijuan, et al.
Publicado: (2022) -
IMB-T130 targets 3-dehydroquinate synthase and inhibits Mycobacterium tuberculosis
por: Zhu, Ningyu, et al.
Publicado: (2018) -
GDF11 promotes osteogenesis as opposed to MSTN, and follistatin, a MSTN/GDF11 inhibitor, increases muscle mass but weakens bone
por: Suh, Joonho, et al.
Publicado: (2020) -
Regulation of Skeletal Muscle Atrophy in Cachexia by MicroRNAs and Long Non-coding RNAs
por: Chen, Rui, et al.
Publicado: (2020) -
Molecular mechanisms of cancer cachexia-induced muscle atrophy
por: Yang, Wei, et al.
Publicado: (2020)